ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma

Lymphoma trials near Barcelona, CT, ESP:

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.ARV-3...

Enrolling
Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
Drug: ARV-393

Phase 1

Arvinas
Arvinas

Barcelona, Spain and 16 other locations

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Obinutuzumab
Drug: CC-99282

Phase 1, Phase 2

Celgene
Celgene

Barcelona, Spain and 68 other locations

Locations recently updated

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Barcelona, Catalonia, Spain and 71 other locations

1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy or for whic...

Enrolling
Lymphoma
Solid Tumor, Adult
Drug: Fadraciclib

Phase 1, Phase 2

Cyclacel Pharmaceuticals

Barcelona, Spain and 3 other locations

pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma...

Enrolling
B-cell Non-Hodgkin Lymphoma
B-cell Lymphoma
Drug: IKS03

Phase 1

Iksuda Therapeutics

Badalona, Spain and 12 other locations

Single-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ci...

Enrolling
DIFFUSE LARGE B-CELL LYMPHOMA
Drug: Axicabtagene Ciloleucel

Phase 2

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Barcelona, Catalonia, Spain and 14 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: vinblastine
Drug: brentuximab vedotin

Phase 3

Takeda
Takeda

Barcelona, Spain and 214 other locations

The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during...

Enrolling
Marginal Zone Lymphoma
Follicular Lymphoma
Biological: rituximab
Biological: EO2463

Phase 1, Phase 2

Enterome

Barcelona, Spain and 11 other locations

on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back af...

Enrolling
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Barcelona, Spain and 162 other locations

phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab...

Enrolling
Large B Cell Lymphoma
Drug: Epcoritamab
Drug: Epcoritamab, tafasitamab and lenalidomide

Phase 2

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Barcelona, Cataluña, Spain and 14 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems